Holdings
Squadron Capital Management LLC
As of Jun 30, 2026, Squadron Capital Management LLC reported 26 positions worth US$259M. Largest: Relmada Therapeutics, Inc., C4 Therapeutics, Inc. and Cogent Biosciences, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Relmada Therapeutics, Inc. | 7.35M | US$50.9M | −1.12M | Jun 30, 2026 |
| C4 Therapeutics, Inc. | 7.2M | US$33.6M | +4.95M | Jun 30, 2026 |
| Cogent Biosciences, Inc. | 865K | US$33.5M | +77,508 | Jun 30, 2026 |
| Kodiak Sciences Inc | 500K | US$19.5M | +120K | Jun 30, 2026 |
| Relay Therapeutics, Inc. | 970K | US$18.1M | +298K | Jun 30, 2026 |
| Zentalis Pharmaceuticals, Inc. | 3.7M | US$17.9M | +69,000 | Jun 30, 2026 |
| Edgewise Therapeutics, Inc. | 290K | US$11.8M | −60,000 | Jun 30, 2026 |
| Maze Therapeutics, Inc. | 335K | US$10M | +77,500 | Jun 30, 2026 |
| Inventiva Sa | 2.44M | US$9.2M | +1.9M | Jun 30, 2026 |
| Enliven Therapeutics, Inc. | 160K | US$8.12M | new | Jun 30, 2026 |